FDA Panel To Address Paclitaxel Safety Concerns

The US FDA will soon hold a meeting to discuss paclitaxel-coated devices to treat peripheral arterial disease. The drug-eluting stents and balloons have been subject to increased scrutiny since a meta-analysis found they were linked to a higher patient mortality rate.

FDA Advisory Committee Feature image

The increased scrutiny of paclitaxel-coated devices to treat peripheral arterial disease (PAD) will continue with an upcoming meeting of the US FDA’s coronary devices advisory panel.

The meeting, which the FDA announced in the April 22 Federal Register, will be held in Gaithersburg, Maryland on June...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America